Search Results - "Beumer, J H"

Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care by Beumer, J H

Get full text

Role of PARP inhibitors in cancer biology and therapy by Davar, D, Beumer, J H, Hamieh, L, Tawbi, H

“…Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of…”
Get more information

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis by Tawbi, H.A., Beumer, J.H., Tarhini, A.A., Moschos, S., Buch, S.C., Egorin, M.J., Lin, Y., Christner, S., Kirkwood, J.M.

“…Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma. We hypothesized that epigenetic modulators will reverse chemotherapy resistance, and…”
Get full text

Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo by Teramachi, J, Silbermann, R, Yang, P, Zhao, W, Mohammad, K S, Guo, J, Anderson, J L, Zhou, D, Feng, R, Myint, K-Z, Maertz, N, Beumer, J H, Eiseman, J L, Windle, J J, Xie, X-Q, Roodman, G D, Kurihara, N

“…We reported that p62 (sequestosome 1) serves as a signaling hub in bone marrow stromal cells (BMSCs) for the formation of signaling complexes, including NFκB,…”
Get full text

Pharmacotherapy in Cancer Patients With HIV/AIDS by Beumer, J H, Venkataramanan, R, Rudek, M A

“…Antiretroviral therapy (ART) has significantly reduced morbidity and increased life expectancy of individuals infected with human immunodeficiency virus (HIV)…”
Get full text

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer by Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K

“…Background: This phase 1 clinical trial was conducted to determine the safety, maximum-tolerated dose (MTD), and pharmacokinetics of imatinib, bevacizumab, and…”
Get full text

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer by Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H

“…Background: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant…”
Get full text

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry by Beumer, J H, Garner, R C, Cohen, M B, Galbraith, S, Duncan, G F, Griffin, T, Beijnen, J H, Schellens, J H M

“…Ixabepilone (BMS-247550) is a semi-synthetic, microtubule stabilizing epothilone B analogue which is more potent than taxanes and has displayed activity in…”
Get full text

Hair as a biological specimen for therapeutic drug monitoring by Beumer, J H, Bosman, I J, Maes, R A

“…To study the potential of hair as a biological specimen in therapeutic drug monitoring (TDM), a review of the correlation between hair concentration, blood…”
Get more information

Hepatotoxicity and metabolism of trabectedin: a literature review by Beumer, J.H., Schellens, J.H.M., Beijnen, J.H.

“…Trabectedin is a promising anticancer drug currently undergoing phase II evaluation. In preclinical studies, trabectedin was found to cause hepatotoxicity and…”
Get full text

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA by Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., Piekarz, R.

Get full text

A Phase I Trial of Isolated Hepatic Perfusion (IHP) Using 5-FU and Oxaliplatin in Patients with Unresectable Isolated Liver Metastases from Colorectal Cancer by Magge, D., Zureikat, A. H., Bartlett, D. L., Holtzman, M. P., Choudry, H. A., Beumer, J. H., Pingpank, J. F., Holleran, J. L., Strychor, S., Cunningham, D. E., Jones, H. L., Zeh, H. J.

“…Background Isolated hepatic perfusion (IHP) with melphalan is an established approach for patients with unresectable metastatic liver lesions. This study…”
Get full text

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice by Beumer, J. H., Franke, N. E., Tolboom, R., Buckle, T., Rosing, H., Lopez-Lazaro, L., Schellens, J. H. M., Beijnen, J. H., van Tellingen, O.

“…Summary Trabectedin is a novel anticancer drug active against soft tissue sarcomas. Trabectedin is a substrate for P-glycoprotein (P-gp), which is encoded by…”
Get full text

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer by Beumer, J H, Rademaker-Lakhai, J M, Rosing, H, Lopez-Lazaro, L, Beijnen, J H, Schellens, J H M

“…Trabectedin (Yondelis, formerly ET-743) is an anti-cancer drug currently undergoing phase II development. Despite extensive pharmacokinetic studies, the human…”
Get full text

Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers by Cattoli, G., Bart, A., van Vugt, R., Pot, R. G. J., Vandenbroucke-Grauls, C. M. J. E., Kuipers, E. J., Kusters, J. G., Klaver, P. S. J., Robijn, R. J., Beumer, H. J., van der Gaag, I.

Get full text

Trabectedin (Yondelis super(TM), formerly ET-743), a mass balance study in patients with advanced cancer by Beumer, J H, Rademaker-Lakhai, J M, Rosing, H, Lopez-Lazaro, L, Beijnen, J H, Schellens, JHM

“…Trabectedin (Yondelis super(TM), formerly ET-743) is an anti-cancer drug currently undergoing phase II development. Despite extensive pharmacokinetic studies,…”
Get full text

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy by Twardowski, Przemyslaw W, Beumer, Jan H, Chen, C.S, Kraft, Andrew S, Chatta, Gurkamal S, Mitsuhashi, Masato, Ye, Wei, Christner, Susan M, Lilly, Michael B

“…There is a need for efficacious therapies for metastatic castration-resistant prostate cancer (mCRPC) after disease progression on docetaxel. The SRC tyrosine…”
Get full text

Biomarkers of Phenethyl Isothiocyanate-Mediated Mammary Cancer Chemoprevention in a Clinically Relevant Mouse Model by SINGH, Shivendra V, KIM, Su-Hyeong, POWOLNY, Anna A, DHIR, Rajiv, SEHRAWAT, Anuradha, ARLOTTI, Julie A, HAHM, Eun-Ryeong, SAKAO, Kozue, BEUMER, Jan H, JANKOWITZ, Rachel C, CHANDRA-KUNTAL, Kumar, LEE, Joomin

“…Phenethyl isothiocyanate (PEITC) is a natural plant compound with chemopreventative potential against some cancers and the ability to induce apoptosis in…”
Get full text

A Proof-of-Principle Histone Deacetylase Inhibitor Trial in Resectable Aerodigestive Tract Cancer: Intratumoral Drug Levels and Biomarker Responses by Dragnev, K., Beumer, J.H., Anyang, B., Ma, T., Galimberti, F., Erkmen, C.P., Nugent, W., Rigas, J., Abraham, K., Johnstone, D., Memoli, V., Dmitrovsky, E.

Get full text

Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM) by Beumer, J. H., Tawbi, H. A., Tarhini, A. A., Moschos, S. J., Egorin, M. J., Buch, S. C., Lin, Y., Kirkwood, J. M.

“…Abstract only…”
Get full text